Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Slightly Bullish +15

Amgen Stock - Weekly outlook with earnings date and pipeline in view - Ad-hoc-news.de

📅 Amgen's next quarterly earnings are anticipated in late July 2026, though no official date has been released yet.

💰 Shares closed at $337.60 on June 18, 2026, with extended-hours trading showing a fractional decline to around $337.00.

🏢 The company holds a market capitalization of approximately $181 billion as of the latest reported close.

💊 Key revenue drivers include Repatha (cholesterol), Prolia (osteoporosis), and an expanding biosimilars portfolio.

🔬 Investors are monitoring pipeline catalysts in obesity, oncology, and inflammation for potential medium-term revenue shifts.

📊 Amgen is a constituent of both the S&P 500 and Nasdaq-100 indices.

🗣️ Management has identified obesity, cardiovascular disease, and oncology as primary growth pillars for future expansion.

Bullish Signals
  • Amgen maintains a substantial market capitalization of $181 billion, reflecting strong investor confidence in its biotechnology portfolio.
  • The company's diversified revenue stream includes established blockbuster drugs like Repatha and Prolia alongside a growing biosimilars business.
  • Pipeline focus on high-priority areas such as obesity (AMG 133) and oncology suggests potential for significant long-term growth catalysts.
Risk Factors
  • Shares traded fractionally lower in extended hours, suggesting cautious sentiment ahead of the upcoming earnings release.
  • No official earnings date has been posted yet, creating uncertainty regarding precise timing for investor expectations.
Full Analysis
Amgen Inc. (AMGN) begins the week with muted news flow, as investors shift focus toward upcoming quarterly earnings expected in late July 2026 and key pipeline developments in obesity, oncology, and inflammation sectors. Shares closed at $337.60 on June 18, 2026, trading slightly lower in extended hours, with the company maintaining its position as a major biotechnology player within the S&P 500 and Nasdaq-100 indices. The company's revenue is primarily driven by innovative biologics including Repatha for cholesterol and Prolia for osteoporosis, alongside a growing portfolio of biosimilars marketed globally. Market attention remains on late-stage drug programs such as AMG 133 (MariTide) and potential updates at medical conferences, which could influence long-term valuation despite the lack of immediate headlines.